MARAbio® Presents New Clinical Findings Linking Maternal Autoantibodies to a Non-Genetic Form of Autism and High Familial Recurrence Risk

PR Newswire

Findings presented at the National Society of Genetic Counselors Annual Conference highlight opportunities for individualized recurrence-risk counseling and earlier clinical evaluation

SALT LAKE CITY, Nov. 16, 2026 /PRNewswire/ — MARAbio Systems, Inc. (MARAbio®), a precision immunology company focused on maternal autoantibody-related autism (MARA), presented new clinical findings at the National Society of Genetic Counselors (NSGC) 45th Annual Conference, held November 10–14 in Baltimore, Maryland. The findings identified specific maternal autoantibody combinations associated with a distinct, non-genetic form of autism and a high risk of recurrence in subsequent children within affected families.

Research indicates that MARA, estimated to account for approximately 10-20% of autism cases, is driven by maternal autoantibodies that cross the placenta and target proteins involved in fetal brain development. Studies suggest that MARA can result in higher severity of autism symptoms and, in certain cases, co-occurring intellectual disability. Identifying these autoantibodies in a mother, even before a future pregnancy, may provide families and healthcare providers with important information about recurrence risk, supporting more individualized counseling, earlier developmental evaluation and timely intervention.

The study, presented at NSGC by Megan Martin, MS, CGC, MARAbio’s Vice President of Operations, analyzed maternal blood samples from two established research cohorts: the Childhood Autism Risks from Genetics and the Environment (CHARGE) Study and the Markers of Autism Risk in Babies – Learning Early Signs (MARBLES) Study. Findings initially identified in CHARGE were subsequently confirmed in MARBLES, strengthening the evidence linking specific maternal autoantibody combinations to MARA. 

“While genetic testing has advanced our understanding of autism, these findings highlight an important non-genetic contributor,” said E. Robert Wassman, MD, a board-certified medical geneticist and Chief Medical Officer of MARAbio. “For families who already have a child with autism, identifying these autoantibodies can provide specific information about recurrence risk in future children, helping clinicians offer more individualized counseling.”

These findings contributed to the development and clinical validation of MARAbio’s commercially available MAR-Autism™ Test, a maternal blood test designed to identify MARA-associated autoantibodies. Clinical validation results presented in October demonstrated 99.8% specificity and 97.5% positive predictive value in the study’s high-risk population, supporting the test’s ability to identify this distinct form of autism within the population studied.

“Our focus is on translating this scientific progress into meaningful clinical information for families,” said Michael Paul, Chief Executive Officer of MARAbio. “With the MAR-Autism Test now commercially available, we are working to expand physician awareness and access, helping families obtain answers sooner and pursue interventions shown to improve outcomes.”

MARAbio continues to advance scientific understanding of MARA and the potential clinical role of maternal autoantibody testing in autism evaluation, recurrence-risk counseling and family planning. The company plans to share additional findings through future scientific publications and presentations.

About the MAR-Autism™ Test

The MAR-Autism™ Test is a maternal blood test designed to identify a distinct, non-genetic form of autism associated with specific maternal autoantibodies. Children with MARA may experience more severe autism symptoms and, in certain cases, have a higher likelihood of co-occurring intellectual disability. Intended for mothers of children diagnosed with or showing signs of autism, the test complements established clinical diagnostic assessments and may provide information relevant to recurrence-risk counseling. The test has not been validated for use during pregnancy.

About MARAbio®

MARAbio Systems, Inc. (MARAbio®) is a precision immunology company focused on advancing the understanding and identification of maternal autoantibody-related autism (MARA). Its first commercial product, the MAR-Autism™ Test, detects maternal autoantibody combinations associated with this distinct form of autism.

For more information about the MAR-Autism Test, visit www.marautism.com.

Media contact: Press@marabio.com 

Cision View original content:https://www.prnewswire.com/news-releases/marabio-presents-new-clinical-findings-linking-maternal-autoantibodies-to-a-non-genetic-form-of-autism-and-high-familial-recurrence-risk-302939398.html

SOURCE MARAbio

About The Author